Corporate Update: Exicure (XCUR) and Peer Performance in the Last 24 Hours
Exicure (XCUR) concluded its trading day on Friday, November 23, 2026, with a modest rise of 1.1 % to a closing price of USD 1.09. The uptick came after the stock had been down 21.71 % since the close of the previous month, illustrating a modest rebound amid a volatile trading environment.
Trading Metrics
- Shares Outstanding: 6.5 million
- Market Capitalization: USD 6.6 million
- Volume: Approximately USD 41 k worth of shares changed hands in the last 24 hours
- Simple Moving Average (200 days): USD 2.89
- 52‑Week High: USD 9.48 (recorded on 12 September 2025)
- 52‑Week Low: USD 0.94 (recorded on 10 September 2026)
These figures suggest that while Exicure’s current trading price remains below its 200‑day average, the company is slowly recovering from a significant decline in the short term.
Peer Performance Snapshot
The market reaction to Exicure’s slight gain is mirrored in the broader biotechnology and medical‑device space:
| Company | Ticker | 24‑Hour Move | Current Price (USD) | Market Cap (USD) |
|---|---|---|---|---|
| Snipp Interactive | SNIPF | –2.31 % | 0.02 | 7.6 million |
| Calcimedica | CALC | +7.98 % | 1.25 | 7.9 million |
| Innovative Eyewear | LUCY | +4.45 % | 0.87 | 7.6 million |
| Curanex | CURX | +5.14 % | 4.78 | 7.9 million |
| Biomerica | BMRA | –1.75 % | 1.68 | 7.9 million |
Calcimedica and Curanex lead the sector with gains above 5 %, while Snipp Interactive and Biomerica experienced modest declines. Exicure’s 1.1 % rise positions it near the middle of this group, indicating a cautious but optimistic investor sentiment.
Company Context
Exicure, Inc. is a clinical‑stage biotechnology firm headquartered in Skokie, United States. The company focuses on developing a novel class of immunomodulatory and gene‑regulating therapeutics aimed at validated targets in oncology, immunology, and dermatology. Its pipeline reflects a commitment to advancing precision medicine, with several candidates currently in pre‑clinical and early clinical phases.
Traded on the Nasdaq exchange, Exicure’s performance reflects the broader challenges faced by early‑stage biotechs—balancing high developmental risk against the potential for breakthrough therapies. Investors monitoring the company will likely focus on upcoming clinical milestones, partnership announcements, and regulatory developments that could materially alter its valuation trajectory.
The information presented herein is based on publicly available market data as of the closing time on 23 November 2026. It is intended for informational purposes only and does not constitute investment advice.
